Paper3202902
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Knox RJ and 3 others. Biochem Pharmacol, 1988. Cited by 148 papers, by iCite.
Cite this record
ConductScience Library. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Papers, record 3202902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3202902
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Aziridines | Major topic |
| Azirines | Major topic |
| Carcinoma 256, Walker | Major topic |
| Cross-Linking Reagents | Major topic |
| DNA Damage | Major topic |
| Nitroreductases | Major topic |
| Oxidoreductases | Major topic |
| Animals | |
| Cell Survival | |
| Cricetinae | |
| NAD | |
| Rats | |
| Tumor Cells, Cultured |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42935498 | Gene therapy as an upcoming technique in the treatment of cancer: A cellular solution to a cellular problem. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42935498 | PubMed |
| 42465319 | Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954. | bioRxiv | 2026 | https://conductscience.org/library/papers/42465319 | PubMed |
| 40940618 | Novel TdsD nitroreductase: characterization of kinetics and substrate specificity. | Biotechnol Lett | 2025 | https://conductscience.org/library/papers/40940618 | PubMed |
| 39368987 | Prodrug activation by 4,4'-bipyridine-mediated aromatic nitro reduction. | Nat Commun | 2024 | https://conductscience.org/library/papers/39368987 | PubMed |
| 37067816 | The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach. | Biosci Rep | 2023 | https://conductscience.org/library/papers/37067816 | PubMed |
| 37047605 | The Crystal Structure of Engineered Nitroreductase NTR 2.0 and Impact of F70A and F108Y Substitutions on Substrate Specificity. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047605 | PubMed |
| 34163368 | Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34163368 | PubMed |
| 33276631 | NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33276631 | PubMed |
| 32979040 | Evaluation of two xenobiotic reductases from Pseudomonas putida for their suitability for magnetic nanoparticle-directed enzyme prodrug therapy as a novel approach to cancer treatment. | Microbiologyopen | 2020 | https://conductscience.org/library/papers/32979040 | PubMed |
| 32093290 | Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32093290 | PubMed |
| 30773488 | Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo. | Stem Cell Reports | 2019 | https://conductscience.org/library/papers/30773488 | PubMed |
| 30695061 | Regeneration of the zebrafish retinal pigment epithelium after widespread genetic ablation. | PLoS Genet | 2019 | https://conductscience.org/library/papers/30695061 | PubMed |
| 29785241 | An In Vivo Zebrafish Model for Interrogating ROS-Mediated Pancreatic β-Cell Injury, Response, and Prevention. | Oxid Med Cell Longev | 2018 | https://conductscience.org/library/papers/29785241 | PubMed |
| 27502282 | Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases. | J Biol Chem | 2016 | https://conductscience.org/library/papers/27502282 | PubMed |
| 25853312 | Potent and tumor specific: arming bacteria with therapeutic proteins. | Ther Deliv | 2015 | https://conductscience.org/library/papers/25853312 | PubMed |
| 24732092 | Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. | Oncotarget | 2014 | https://conductscience.org/library/papers/24732092 | PubMed |
| 24202330 | The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. | Cancers (Basel) | 2013 | https://conductscience.org/library/papers/24202330 | PubMed |
| 23542552 | The nitroreductase system of inducible targeted ablation facilitates cell-specific regenerative studies in zebrafish. | Methods | 2013 | https://conductscience.org/library/papers/23542552 | PubMed |
| 22914496 | Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging. | Gene Ther | 2013 | https://conductscience.org/library/papers/22914496 | PubMed |
| 22365330 | Cellular senescence and cancer chemotherapy resistance. | Drug Resist Updat | 2012 | https://conductscience.org/library/papers/22365330 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3202902
GET https://conductscience.org/api/papers/v1/3202902/cited_by?page=2